BACKGROUND: Claudins are tight junction proteins expressed in epithelial tissues that play important roles in cell polarity and adhesion. Altered distribution of claudin-1(CLDN1) affects cell mobility and tumor invasiveness. Craniopharyngiomas (CPs) represent epithelial tumors of the sellar region, consisting of adamantinomatous (adaCP) and papillary (papCP) variants. Their tendency to infiltrate surrounding brain structures complicates successful surgery. Reliable markers are required to predict tumor behavior and to establish individualized treatment protocols. METHODS: We describe the distribution pattern of CLDN1 in a large cohort of 66 adaCPs, 21 papCPs, and 24 Rathke`s cleft cyst (RCC) cases using immunohistochemistry. CLDN1 mRNA levels were analyzed with qRT-PCR in 33 CP samples. The impact on the migration potential was studied in primary adaCP cell cultures (n = 11) treated with small interfering RNA (siRNA) for CLDN1. Furthermore, CLDN1 distribution patterns and expression levels were compared between invasive (n = 16) and noninvasive (n = 17) tumor groups. RESULTS: PapCPs and RCCs exhibited a distinct homogenous and membranous expression pattern, whereas CLDN1 immunoreactivity appeared weaker and more heterogeneous in adaCPs. In the latter cases, whirl-like cell clusters showed complete absence of CLDN1. mRNA analysis confirmed reduced CLDN1 levels in adaCPs versus papCPs. Interestingly, invasive tumors exhibited significantly lower CLDN1 expression compared with noninvasive counterparts regardless of CP subtype. Accordingly, siRNA treatment for CLDN1 altered tumor cell migration in vitro. CONCLUSION: CLDN1 represents a novel marker in the differential diagnosis of CP variants and RCCs. Low CLDN1 expression levels correlate with an invasive CP growth pattern and may serve as a prognostic marker.
BACKGROUND: Claudins are tight junction proteins expressed in epithelial tissues that play important roles in cell polarity and adhesion. Altered distribution of claudin-1(CLDN1) affects cell mobility and tumor invasiveness. Craniopharyngiomas (CPs) represent epithelial tumors of the sellar region, consisting of adamantinomatous (adaCP) and papillary (papCP) variants. Their tendency to infiltrate surrounding brain structures complicates successful surgery. Reliable markers are required to predict tumor behavior and to establish individualized treatment protocols. METHODS: We describe the distribution pattern of CLDN1 in a large cohort of 66 adaCPs, 21 papCPs, and 24 Rathke`s cleft cyst (RCC) cases using immunohistochemistry. CLDN1 mRNA levels were analyzed with qRT-PCR in 33 CP samples. The impact on the migration potential was studied in primary adaCP cell cultures (n = 11) treated with small interfering RNA (siRNA) for CLDN1. Furthermore, CLDN1 distribution patterns and expression levels were compared between invasive (n = 16) and noninvasive (n = 17) tumor groups. RESULTS: PapCPs and RCCs exhibited a distinct homogenous and membranous expression pattern, whereas CLDN1 immunoreactivity appeared weaker and more heterogeneous in adaCPs. In the latter cases, whirl-like cell clusters showed complete absence of CLDN1. mRNA analysis confirmed reduced CLDN1 levels in adaCPs versus papCPs. Interestingly, invasive tumors exhibited significantly lower CLDN1 expression compared with noninvasive counterparts regardless of CP subtype. Accordingly, siRNA treatment for CLDN1 altered tumor cell migration in vitro. CONCLUSION:CLDN1 represents a novel marker in the differential diagnosis of CP variants and RCCs. Low CLDN1 expression levels correlate with an invasive CP growth pattern and may serve as a prognostic marker.
Authors: A Pierre-Kahn; C Recassens; G Pinto; C Thalassinos; S Chokron; J C Soubervielle; R Brauner; M Zerah; C Sainte Rose Journal: Childs Nerv Syst Date: 2005-07-28 Impact factor: 1.475
Authors: J D Schulzke; A H Gitter; J Mankertz; S Spiegel; U Seidler; S Amasheh; M Saitou; S Tsukita; M Fromm Journal: Biochim Biophys Acta Date: 2005-05-15
Authors: R K Crowley; O P Hamnvik; E P O'Sullivan; L A Behan; D Smith; A Agha; C J Thompson Journal: Clin Endocrinol (Oxf) Date: 2010-10 Impact factor: 3.478
Authors: Bernd M Hofmann; Jürgen Kreutzer; Wolfgang Saeger; Michael Buchfelder; Ingmar Blümcke; Rudolf Fahlbusch; Rolf Buslei Journal: Am J Surg Pathol Date: 2006-12 Impact factor: 6.394
Authors: Carles Gaston-Massuet; Cynthia Lilian Andoniadou; Massimo Signore; Sujatha A Jayakody; Nicoletta Charolidi; Roger Kyeyune; Bertrand Vernay; Thomas S Jacques; Makoto Mark Taketo; Paul Le Tissier; Mehul T Dattani; Juan Pedro Martinez-Barbera Journal: Proc Natl Acad Sci U S A Date: 2011-06-02 Impact factor: 11.205
Authors: Anna-Mária Tokés; Janina Kulka; Sándor Paku; Agnes Szik; Csilla Páska; Pál Kaposi Novák; László Szilák; András Kiss; Krisztina Bögi; Zsuzsa Schaff Journal: Breast Cancer Res Date: 2005-01-31 Impact factor: 6.466
Authors: Teresa Lopardo; Nadia Lo Iacono; Barbara Marinari; Maria L Giustizieri; Daniel G Cyr; Giorgio Merlo; Francesca Crosti; Antonio Costanzo; Luisa Guerrini Journal: PLoS One Date: 2008-07-23 Impact factor: 3.240
Authors: J Hartmann; J Wölfelschneider; C Stache; R Buslei; A Derer; M Schwarz; T Bäuerle; R Fietkau; U S Gaipl; C Bert; A Hölsken; B Frey Journal: Strahlenther Onkol Date: 2016-07-11 Impact factor: 3.621
Authors: Fei Liu; Michael Koval; Shoba Ranganathan; Susan Fanayan; William S Hancock; Emma K Lundberg; Ronald C Beavis; Lydie Lane; Paula Duek; Leon McQuade; Neil L Kelleher; Mark S Baker Journal: J Proteome Res Date: 2016-01-12 Impact factor: 4.466
Authors: Vivian Thimsen; Annett Hölsken; Michael Buchfelder; Jörg Flitsch; Rudolf Fahlbusch; Harald Stefanits; Marco Losa; David T W Jones; Rolf Buslei Journal: Sci Rep Date: 2016-07-19 Impact factor: 4.379